Did Biogen's Kingsley Take Blame For Tecfidera Sales?
This article was originally published in Scrip
Executive Summary
The timing of Biogen's Oct. 9 announcement that Tony Kingsley, executive vice president of global commercial operations, is leaving the company came at an unfortunate time – just weeks before third quarter earnings will reveal whether Tecfidera (dimethyl fumarate) sales are growing, stable or sliding.